194 related articles for article (PubMed ID: 15150277)
1. Reversal of the hypomethylation status of urokinase (uPA) promoter blocks breast cancer growth and metastasis.
Pakneshan P; Szyf M; Farias-Eisner R; Rabbani SA
J Biol Chem; 2004 Jul; 279(30):31735-44. PubMed ID: 15150277
[TBL] [Abstract][Full Text] [Related]
2. Methylation and inhibition of expression of uPA by the RAS oncogene: divergence of growth control and invasion in breast cancer cells.
Pakneshan P; Szyf M; Rabbani SA
Carcinogenesis; 2005 Mar; 26(3):557-64. PubMed ID: 15618232
[TBL] [Abstract][Full Text] [Related]
3. Regulation of DNA methylation in human breast cancer. Effect on the urokinase-type plasminogen activator gene production and tumor invasion.
Guo Y; Pakneshan P; Gladu J; Slack A; Szyf M; Rabbani SA
J Biol Chem; 2002 Nov; 277(44):41571-9. PubMed ID: 12198113
[TBL] [Abstract][Full Text] [Related]
4. Methylation status of uPA promoter as a molecular mechanism regulating prostate cancer invasion and growth in vitro and in vivo.
Pakneshan P; Xing RH; Rabbani SA
FASEB J; 2003 Jun; 17(9):1081-8. PubMed ID: 12773490
[TBL] [Abstract][Full Text] [Related]
5. Demethylation of urokinase promoter as a prognostic marker in patients with breast carcinoma.
Pakneshan P; Têtu B; Rabbani SA
Clin Cancer Res; 2004 May; 10(9):3035-41. PubMed ID: 15131040
[TBL] [Abstract][Full Text] [Related]
6. Transcriptional regulation of urokinase (uPA) gene expression in breast cancer cells: role of DNA methylation.
Xing RH; Rabbani SA
Int J Cancer; 1999 May; 81(3):443-50. PubMed ID: 10209960
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory effect of S-adenosylmethionine on the growth of human gastric cancer cells in vivo and in vitro.
Zhao Y; Li JS; Guo MZ; Feng BS; Zhang JP
Chin J Cancer; 2010 Aug; 29(8):752-60. PubMed ID: 20663323
[TBL] [Abstract][Full Text] [Related]
8. Hypomethylation of urokinase (uPA) promoter in breast and prostate cancer: prognostic and therapeutic implications.
Pakneshan P; Szyf M; Rabbani SA
Curr Cancer Drug Targets; 2005 Nov; 5(7):471-88. PubMed ID: 16305345
[TBL] [Abstract][Full Text] [Related]
9. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.
Han B; Nakamura M; Zhou G; Ishii A; Nakamura A; Bai Y; Mori I; Kakudo K
Int J Oncol; 2006 Apr; 28(4):807-14. PubMed ID: 16525628
[TBL] [Abstract][Full Text] [Related]
10. Demethylation-linked activation of urokinase plasminogen activator is involved in progression of prostate cancer.
Pulukuri SM; Estes N; Patel J; Rao JS
Cancer Res; 2007 Feb; 67(3):930-9. PubMed ID: 17283123
[TBL] [Abstract][Full Text] [Related]
11. Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87).
Krüger A; Soeltl R; Lutz V; Wilhelm OG; Magdolen V; Rojo EE; Hantzopoulos PA; Graeff H; Gänsbacher B; Schmitt M
Cancer Gene Ther; 2000 Feb; 7(2):292-9. PubMed ID: 10770639
[TBL] [Abstract][Full Text] [Related]
12. Direct evidence of the importance of stromal urokinase plasminogen activator (uPA) in the growth of an experimental human breast cancer using a combined uPA gene-disrupted and immunodeficient xenograft model.
Frandsen TL; Holst-Hansen C; Nielsen BS; Christensen IJ; Nyengaard JR; Carmeliet P; Brünner N
Cancer Res; 2001 Jan; 61(2):532-7. PubMed ID: 11212246
[TBL] [Abstract][Full Text] [Related]
13. Interleukin enhancer-binding factor 3 promotes breast tumor progression by regulating sustained urokinase-type plasminogen activator expression.
Hu Q; Lu YY; Noh H; Hong S; Dong Z; Ding HF; Su SB; Huang S
Oncogene; 2013 Aug; 32(34):3933-43. PubMed ID: 22986534
[TBL] [Abstract][Full Text] [Related]
14. Synergistic anti-breast cancer effect of a combined treatment with the methyl donor S-adenosyl methionine and the DNA methylation inhibitor 5-aza-2'-deoxycytidine.
Chik F; Machnes Z; Szyf M
Carcinogenesis; 2014 Jan; 35(1):138-44. PubMed ID: 23985780
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of human breast cancer cell invasion by siRNA against urokinase-type plasminogen activator.
Huang HY; Jiang ZF; Li QX; Liu JY; Wang T; Zhang R; Zhao J; Xu YM; Bao W; Zhang Y; Jia LT; Yang AG
Cancer Invest; 2010 Aug; 28(7):689-97. PubMed ID: 20636107
[TBL] [Abstract][Full Text] [Related]
16. Downregulation of miR-193b contributes to enhance urokinase-type plasminogen activator (uPA) expression and tumor progression and invasion in human breast cancer.
Li XF; Yan PJ; Shao ZM
Oncogene; 2009 Nov; 28(44):3937-48. PubMed ID: 19701247
[TBL] [Abstract][Full Text] [Related]
17. Modulation of protein expression levels and DNA methylation status of breast cancer metastasis genes by anthracycline-based chemotherapy and the demethylating agent decitabine.
Ari F; Napieralski R; Ulukaya E; Dere E; Colling C; Honert K; Krüger A; Kiechle M; Schmitt M
Cell Biochem Funct; 2011 Dec; 29(8):651-9. PubMed ID: 21887697
[TBL] [Abstract][Full Text] [Related]
18. cDNA transfection of amino-terminal fragment of urokinase efficiently inhibits cancer cell invasion and metastasis.
Zhu F; Jia S; Xing G; Gao L; Zhang L; He F
DNA Cell Biol; 2001 May; 20(5):297-305. PubMed ID: 11410166
[TBL] [Abstract][Full Text] [Related]
19. Effects of specific DNMT gene depletion on cancer cell transformation and breast cancer cell invasion; toward selective DNMT inhibitors.
Chik F; Szyf M
Carcinogenesis; 2011 Feb; 32(2):224-32. PubMed ID: 20980350
[TBL] [Abstract][Full Text] [Related]
20. Maspin regulates hypoxia-mediated stimulation of uPA/uPAR complex in invasive breast cancer cells.
Amir S; Margaryan NV; Odero-Marah V; Khalkhali-Ellis Z; Hendrix MJ
Cancer Biol Ther; 2005 Apr; 4(4):400-6. PubMed ID: 15846059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
